Group 1 - Baiyang Pharmaceutical has experienced a decline for four consecutive trading days, with a cumulative drop of -3.93% [1] - The company, established in 2005, focuses on the development, manufacturing, and commercialization of medical innovations, aiming to optimize healthcare through technological advancements [1] - ICBC Credit Suisse Asset Management has two funds among the top ten shareholders of Baiyang Pharmaceutical, with one fund reducing its holdings and the other entering the position in the second quarter of this year [1] Group 2 - ICBC Credit Suisse Fund's "ICBC Frontier Medical Stock A" has a year-to-date return of 33.52%, ranking 190 out of 976 in its category, while "ICBC Healthcare Stock" has a return of 32.51%, ranking 206 out of 976 [2] - The fund managers for these funds are Zhao Bei and Ding Yang, with Zhao having over ten years of experience in the industry and currently managing multiple funds [5][6] - Ding Yang, who joined ICBC Credit Suisse in December 2017, has been managing the healthcare industry stock fund since May 2023 [7]

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown significant returns over various time frames [1] - The fund's latest net value is 2.8960 yuan, with a recent decline of 0.62%. Over the past month, the fund has achieved a return of 6.78%, ranking 325 out of 656 in its category. In the last six months, the return was 25.80%, ranking 82 out of 637, and since the beginning of the year, it has returned 27.07%, ranking 113 out of 635 [1] - The top ten holdings of the fund account for a total of 44.59%, with significant positions in companies such as Heng Rui Pharmaceutical (7.52%), Kelun Pharmaceutical (6.50%), and BeiGene (5.08%) [1] Group 2 - The fund was established on November 18, 2014, and as of June 30, 2025, it has a total scale of 2.797 billion yuan. The fund managers are Zhao Bei and Ding Yang [1] - Zhao Bei holds a master's degree and has extensive experience in the healthcare sector, having been the fund manager since the fund's inception. Ding Yang, a PhD holder, joined the company in December 2017 and has been involved in various fund management roles [2]

Group 1 - The core point of the news is the performance and holdings of the Industrial and Commercial Bank of China (ICBC) Healthcare Stock Fund, which has shown significant returns over various time frames despite a recent decline in net value [1] - As of August 7, 2025, the fund's latest net value is 2.8960 yuan, reflecting a decrease of 2.03%. The fund has achieved a return of 10.32% over the past month, ranking 242 out of 1022 in its category. Over the last six months, the return is 26.13%, ranking 113 out of 985, and since the beginning of the year, the return is 27.07%, ranking 155 out of 975 [1] - The top ten holdings of the ICBC Healthcare Stock Fund account for a total of 44.59%, with significant positions in companies such as Heng Rui Medicine (7.52%), Kelun Pharmaceutical (6.50%), and BeiGene (5.08%) [1] Group 2 - The ICBC Healthcare Stock Fund was established on November 18, 2014, and as of June 30, 2025, it has a total scale of 2.797 billion yuan. The fund is managed by Zhao Bei and Ding Yang [1] - Zhao Bei holds a master's degree and has extensive experience in healthcare investment, having been with ICBC Credit Suisse since 2010 and managing the healthcare fund since its inception [2] - Ding Yang, a PhD holder, joined ICBC Credit Suisse in December 2017 and has been involved in managing various funds, including the healthcare sector since May 2023 [2]

简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今,担任工银瑞 信前沿医疗股票型基金基金经理。2018年7月30日至2019年12月23日起担任工银瑞信医药健康行业股票 型证券投资基金基金经理。2020年05月20日至2022年6月14日担任工银瑞信科技创新6个月定期开放混合 型证券投资基金基金经理。2025年4月9日起担任工银瑞信新经济灵活配置混合型证券投资基金(QDII)基 金经理。丁洋先生:中国国籍,博士研究生。曾任加州大学圣地亚哥分校博士后研究员;2017年12月1日加 入工银瑞信基金管理有限公司,现担任研究部基金经理助理、基金经理。2023年5月5日至今,担任工银瑞 信医疗保健行业股票型证券投资基金基金经理。 来源：金融界 金融界2025年7月30日消息，工银医疗保健股票(000831) 最新净值2.9710元，下跌0.74%。该基金近1个 月收益率13. ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1][3] - The latest net value of the fund is 2.9160 yuan, reflecting a growth of 2.50%. The fund's return over the past month is 12.94%, ranking 280 out of 1035 in its category. Over the past six months, the return is 29.37%, ranking 125 out of 1001, and since the beginning of the year, the return is 27.95%, ranking 148 out of 991 [1] - The top ten holdings of the fund account for a total of 44.59%, with significant investments in companies such as Heng Rui Pharmaceutical (7.52%), Kelun Pharmaceutical (6.50%), and BeiGene (5.08%) [1] Group 2 - The fund was established on November 18, 2014, and as of June 30, 2025, it has a total scale of 2.797 billion yuan. The fund managers are Zhao Bei and Ding Yang [1] - Zhao Bei has extensive experience in the healthcare sector, having served as the fund manager for various healthcare-related funds since 2014, while Ding Yang joined the company in December 2017 and has been involved in managing healthcare investment funds [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Healthcare Stock Fund, which has shown a recent net value increase and varying returns over different time frames [1] - As of June 30, 2025, the fund's latest net value is 2.6120 yuan, reflecting a growth of 1.16%. The fund has a one-month return of -1.55%, a six-month return of 14.61%, and a year-to-date return of 14.61% [1] - The fund's top ten holdings account for a total of 39.79%, with significant positions in companies such as Heng Rui Pharmaceutical (8.90%), WuXi AppTec (5.12%), and Aier Eye Hospital (4.94%) [1] Group 2 - The Industrial and Commercial Bank of China Healthcare Stock Fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan [1] - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector and investment management [2]

Core Insights - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China (ICBC) Healthcare Stock Fund, highlighting its recent net value, returns, and top holdings [1]. Fund Performance - The latest net value of ICBC Healthcare Stock Fund is 2.5760 yuan, reflecting a growth of 1.18% - The fund's return over the past month is -0.46%, ranking 514 out of 1026 in its category - Over the last six months, the fund has achieved a return of 11.85%, ranking 173 out of 993 - Year-to-date, the fund has returned 13.03%, ranking 137 out of 997 [1]. Fund Holdings - The top ten holdings of the ICBC Healthcare Stock Fund account for a total of 39.79%, with the following key positions: - Heng Rui Medicine: 8.90% - WuXi AppTec: 5.12% - Aier Eye Hospital: 4.94% - BeiGene: 3.77% - Zai Lab: 3.52% - New Horizon Health: 3.27% - Mindray Medical: 2.80% - Yuyue Medical: 2.76% - United Imaging Healthcare: 2.47% - Innovent Biologics: 2.24% [1]. Fund Management - The ICBC Healthcare Stock Fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan - The fund is managed by Zhao Bei and Ding Yang, with Zhao having extensive experience in healthcare research and fund management [2].

Core Viewpoint - ICBC Medical Care Stock (000831) has experienced a decline of 1.27% on June 19, with a latest net value of 2.56 yuan, marking a cumulative drop of 7.84% over five consecutive trading days [1] Group 1: Fund Performance - The fund was established in November 2014, with a total scale of 2.724 billion yuan and a cumulative return of 156.40% since inception [1] - As of the end of 2024, institutional investors hold 0.41 million shares, accounting for 3.55% of total shares, while individual investors hold 11.19 million shares, making up 96.45% of total shares [1] Group 2: Fund Management - Current fund manager Zhao Bei has a master's degree and has been with ICBC Credit Suisse since 2010, serving as the fund manager since November 18, 2014 [2] - The current fund manager Ding Yang holds a doctoral degree and joined ICBC Credit Suisse in December 2017, taking over as fund manager on May 5, 2023 [2] Group 3: Portfolio Holdings - As of March 31, 2025, the top ten holdings of ICBC Medical Care Stock account for a total of 39.79%, with major positions including: - Heng Rui Medicine (8.90%) - WuXi AppTec (5.12%) - Aier Eye Hospital (4.94%) - BeiGene (3.77%) - Zai Lab (3.52%) - New Horizon Health (3.27%) - Mindray Medical (2.80%) - Yuwell Medical (2.76%) - United Imaging Healthcare (2.47%) - Innovent Biologics (2.24%) [3]

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive returns in various time frames [1] - The latest net value of the fund is 2.7270 yuan, with a growth of 1.79% [1] - The fund's performance over the past month has yielded a return of 8.91%, ranking 96 out of 1025 in its category [1] - Over the last six months, the fund has achieved a return of 13.01%, ranking 146 out of 989 [1] - Year-to-date, the fund has returned 19.66%, ranking 96 out of 999 [1] Group 2 - The top ten holdings of the fund account for a total of 39.79%, with significant positions in companies such as Heng Rui Pharmaceutical (8.90%) and WuXi AppTec (5.12%) [1] - The fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan [1] - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector [2]

Core Viewpoint - The article discusses the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, highlighting its recent net value, returns, and top holdings [1]. Fund Performance - The latest net value of the ICBC Medical Healthcare Stock Fund is 2.5580 yuan, reflecting a decrease of 1.16% - The fund's return over the past month is 3.52%, ranking 172 out of 940 in its category - Over the last six months, the return is 9.79%, with a ranking of 202 out of 914 - Year-to-date, the return stands at 12.24%, ranking 98 out of 926 [1]. Fund Holdings - The top ten holdings of the ICBC Medical Healthcare Stock Fund account for a total of 39.79%, with the following key positions: - Heng Rui Medicine: 8.90% - WuXi AppTec: 5.12% - Aier Eye Hospital: 4.94% - BeiGene: 3.77% - Zai Lab: 3.52% - New Horizon Health: 3.27% - Mindray Medical: 2.80% - Yuwell Medical: 2.76% - United Imaging Healthcare: 2.47% - Innovent Biologics: 2.24% [1]. Fund Management - The ICBC Medical Healthcare Stock Fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector [1][2].